Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As China Prices Drop, Junshi Looks To Coherus To Take PD-1 Global

Execs See China Deal Structure, Valuation Evolving

Executive Summary

After Novartis, US firm Coherus leaps into the China immuno-oncology fray by licensing rights to innovative drugs from Shanghai's Junshi.

You may also be interested in...



Coherus’ Pegfilgrastim Sales Fall $150m In 2021 As Firm Plans On-Body

Coherus BioSciences has posted a massive loss for 2021 due to tumbling revenues, as well as continued investment in its pipeline projects, not least the proposed on-body injector device for its pegfilgrastim biosimilar alongside a ranibizumab asset.

Deal Watch: Bristol, Pfizer Lead Off J.P. Morgan Week With Two Deals Apiece

Despite no mega-deals (yet), the J.P. Morgan Healthcare Conference’s first day brings the usual flurry of deals, including a pair of tie-ups each for Bristol and Pfizer. BioNTech moves into cancer with Crescendo.

EQRx Aims To Dent Saturated, But Still Expensive, PD-1 Market

EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC143756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel